The role of nitric oxide and its donors in uterus contractility regulation

Abstract

This article presents comprehensive data on uterine contractility regulation by nitric oxide, including systematized contemporary data on the status and function of the human nitroxidergic vasodilator system, and our experience in threat of pregnancy interruption management by nitroglycerin given with the transdermal therapeutic system Deponit 5 (Schwarz Pharma, Germany). To control contractile uterine activity in pregnant women with pathologic preliminary period, the authors successfully used sublingual application of Nitrolingual aerosol (G. Pohl-Boskamp GmbH and Co, Germany) with prolongation of the effect by the Deponit system 5. As little as five minutes after aerosol application tocography revealed a decrease in uterine contraction frequency, duration and intensity. By effecting post- and preloading and lowering the resistance of spiral arteries, vasodilators provided increased intensity of placenta circulation, which had a great importance for anteintranatal care of the fetus and newborn. The advantages of nitric oxide donator application in obstetrics were also demonstrated.

Keywords

nitric oxide / uterus / nitroxidergic vasodilator system / nitroglycerin / Deponit 5

References

[1] Abrams J. (Ed.): A symposium: nitroglycerin therapy-contemporary perspective.//Am. J. Cardiol.-1987.- Vol.-6O: 1H-48H.

[2] Andronic-Lion A., Boucher J. L., Detoforge M. et ol.//Biochem. Biophys. Res. Commun. -1992-185: 452-458.

[3] Barnes F//Br. Med. J.-l881-1: 377.

[4] Вult H., Boeckxstaens G. E., Pelckmans P. A., Jordaens F. H. et al. //Nature (Land)-1990-345:346-347.

[5] Buss R., Pohl U, Mutsch A. and Bassenge E.//J. Cardiovosc. PharmacoL- 1989-14: S.81-S85.

[6] Cocks T., Angus L., Campbell J. et al.// J. Cell. Physiol. 1985-123: 310-320.

[7] Feelisch M. and Noack E//Eur. J. Pharmacol.-l 987-139: 19-30.

[8] Fleming I., Gray G. A., Julou-Schoeffer G., Parrott J. R. and Stodet J.-C.// Biochem. Biophys. Res. Commun.-1990- 171:562-568.

[9] Furchgott R. F. and Zovadzki J. V.// Nature-1980-288:373.

[10] Furchgott R. F.//Rev. Pharmacol. Toxicol.-1984-24: 175-197.

[11] Griffith T, Edwards D., Lewis M. et al.//Nature (Lond.)-1984-308: 645-647.

[12] Gruetter C. A., Barry В. K, Gruetter P. Y. et al.//J. Cyclic Nucleotide Res.- 1979-5: 211-224.

[13] Polmer R.//Br. J. Pharmacol.-1986.-87: 685-694.

[14] Hibbs J. B., Lambert L. H., Remington J. S.//Science.-1972-177: 998-1000.

[15] Hibbs J. B., Taintor R. R. and Vavrin Z.//Biochem. Biophys. Res. Commun.- 1984-123:716-723.

[16] Hibbs J. B., Taintor R. R. and Vavrin Z.//Science.-1987.-235: 473-476.

[17] Hibbs J. B., Taintor R. R. Vavrin Z. and Rachlin E. M.//Biochem. Biophys. Res. Commun.-1988-157: 87-94.

[18] Higgs E. A., Moncada S., Vane J. R. et al. //Prostaglandins. -1978-16: 17-22.

[19] Hutchinson P. J. A., Palmer R. M. J. and Moncada S.//Eur. J. PharmacoL- 1987-141:445-451.

[20] Ignarro L. J., Buga G. M., Wood K.S., Byrns R. E. et al.//Proc. Natl. Acad. Sei. USA.-l987-84: 9265-9269.

[21] Ishii K., Gorsky L. D., Forstermann U. et al.//J. Appt. Cardiol.-1989-4:505- 512.

[22] Katsuki S., Arnold W., Mittal C. and Murad F.//J. Cyclic Nucleotide Res.- 1977-3: 23-25.

[23] Keim M. and Schrader J.//Eur. J. Pharmacol. - 1988-155:313-316.

[24] Keim M., Feelisch M., Spahr R., Piper H.-M. et al.//Biochem. Biophys. Res. Commun. -1988-154:236-244.

[25] Luscher T. F., Raij L. and Vanhoutte P. M.//J. Hypertens. -1987-5: S153-S155.

[26] Luscher T. F., Richard V. and Yang Z.//1 Cardiovosc. Pharmacol. -1989-14 (suppl.ll): S76-S80.

[27] Marietta V. A., Yoon P. S., Iyengar R. et al.//Biochem.-1988-27: 8706.

[28] Moncada S., Palmer R. M. J. and Higgs E. A.//Biochem. Pharmacol.-l 989- 38: 1709-1715.

[29] Moncada S., Palmer R. M. J. and Higgs E. A//PharmacoL Rev.-1991- 43(2): 109-142.

[30] Mulsch A., Schray-Utz B., Mordvintcev P. J. et al//FEBS Lett.-1993-321(2): 215- 218.

[31] Murrel W.//Lancet-1879-1: 80.

[32] Schcuk H., Klein M.,Erdriigger W. et at.//Proc. Not. Acad. Sei. USA-1994-91: 1672-1676.

[33] Schultz K. D., Schultz K. and Schultz G.//Nature (Lond.)-1977-265: 750-751.

[34] Schultz R. M., Smith J. A. and Moncada S.//Br. J. Pharmacol., 1991.

[35] Seidel C. L. et at.//Cire. Res.-1987- 60: 626-630.

[36] Sherman M. P., Aeberhord E. E., Wang V. Z. et al.//Biochem. Biophys. Res. Commun.-1993-191(3): 1301-1308.

[37] Shirasaki Y. and Su C.//Eur. J. ParmacoL-1985-114: 93-96.

[38] Stuehr D. J., Cho H. J., Kwon N. S. et al.//Proc. Naff Acad. Sei. USA-1991-88: 7733-7777.

[39] Tay eh M. A. and Marietta M. A.//J Biol. Chem. -1989-264: 19654-19658.

[40] Thiemermann C. and Vane J.//Eur. J. Pharmacol. 1990-182:591-595.

[41] Toda N, Ayo/iki K. and Oka mura Т/ /Am. J. Physiol.-1993-265: Hl03-H107.

[42] Toda N. and Okamura T.//News Physiol. Sei.-1992-7: 148-152.

[43] Tolins G., Palmer R. M. J., Moncada S. et al.//Am. J. Physiol.-1990-258: H655-H662.

[44] Vallance P. and Moncada S.// Lancet-1991-337: 776-778.

[45] Vallance P., Collier J. and Moncada S.//Cardiovasc. Res.-l989.-23: 1053- 1057.

[46] Wagner D. A., Young V. R. and Tannenbaum S. R.//Proc. Naff. Acad. Sei. USA-1983.-80: 4518-4521.

[47] Waldman S. A., Rapoport R. M. and Murad F.//Biochem. Pharmacol.-1986- 35: 3525-3531.

[48] Wessen A., Elowsson P., Axemo P., Lindberg B.//Acta Anaesthesiol. Scand.- 1995-39(6): 847-849.

[49] Yallampalli C., Byam-Smith M. M. S, Nelson S. O. et al.//Endocrinol.-1994- 134(4): 1971-1974.

RIGHTS & PERMISSIONS

Eсо-Vector